Estrogen patches used for menopausal hormone therapy are facing significant supply shortages across the United States, according to a report by PBS. The shortage comes as demand for hormone replacement therapy has surged in recent years, driven by increased awareness of menopause treatment options and growing numbers of women entering perimenopause and menopause.
The supply disruption affects transdermal estrogen patches, a popular delivery method for hormone therapy that allows estrogen to be absorbed directly through the skin. This formulation is often preferred by patients and physicians because it bypasses the liver and may carry lower risks of blood clots compared to oral estrogen tablets. Multiple manufacturers have reported backorders and limited availability of various dosage strengths.
The shortage reflects a broader shift in attitudes toward menopausal hormone therapy. After decades of declining use following concerning findings from the Women’s Health Initiative study in 2002, hormone therapy has experienced a resurgence as newer research has provided more nuanced understanding of its risks and benefits. Celebrity advocacy and increased public discussion about menopause have also contributed to more women seeking treatment for symptoms like hot flashes, night sweats, and sleep disturbances.
For patients currently using estrogen patches, healthcare providers recommend not discontinuing therapy abruptly. Women experiencing difficulty obtaining their prescribed patches should contact their physicians to discuss alternatives, which may include switching to different estrogen formulations such as gels, sprays, or oral medications. Pharmacists may also be able to help locate available inventory at different locations or suggest therapeutic equivalents.
The shortage highlights vulnerabilities in the pharmaceutical supply chain and the challenges of meeting rapidly changing demand for essential medications. As the population ages and more women seek relief from menopausal symptoms, ensuring adequate supply of hormone therapy options will be crucial for women’s health care in the coming years.
